Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. (PubMed, Cancer Metab) - Jun 17, 2025 - "This study highlights a critical role for CAFs in mediating resistance to ALK-TKIs by reprogramming lipid metabolism in ALK-rearranged lung cancer cells. It suggests that targeting these metabolic vulnerabilities, particularly through inhibition of lipid metabolism or induction of ferroptosis, could provide a novel therapeutic approach to overcome resistance and improve patient outcomes."
Journal • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAFs • NRG1
|
|
Almut Schulze; Ann-Kathrin Daum; Holger Sültmann; Lisa Schlicker; Marc A Schneider; Michael Thomas; Petros Christopoulos; Thomas Muley; Ursula Klingmüller
|